{"id":"amiodarone-i-v","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Thyroid dysfunction (hypo- or hyperthyroidism)"},{"rate":"1-5%","effect":"Pulmonary toxicity (pneumonitis, fibrosis)"},{"rate":"1-3%","effect":"Hepatotoxicity"},{"rate":"up to 100% (usually asymptomatic)","effect":"Corneal microdeposits"},{"rate":"10-25%","effect":"Photosensitivity"},{"rate":"3-5%","effect":"Bradycardia"},{"rate":"variable","effect":"QT prolongation"},{"rate":"<1%","effect":"Torsades de pointes"},{"rate":"5-10%","effect":"Nausea and gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL1083993","moleculeType":"Small molecule","molecularWeight":"681.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone's primary mechanism involves inhibition of potassium efflux, which lengthens the action potential duration and effective refractory period of cardiac tissue. It also exhibits properties of Class I (sodium channel blockade), Class II (beta-adrenergic antagonism), and Class IV (calcium channel blockade) antiarrhythmics, making it a broad-spectrum agent. This multi-channel activity makes it effective for suppressing both atrial and ventricular arrhythmias.","oneSentence":"Amiodarone is a Class III antiarrhythmic that blocks potassium channels to prolong the action potential and refractory period, with additional effects on sodium, calcium, and beta-adrenergic channels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:06.475Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation (acute conversion and maintenance of sinus rhythm)"},{"name":"Ventricular tachycardia and ventricular fibrillation"},{"name":"Supraventricular tachycardia"},{"name":"Prevention of recurrent arrhythmias in high-risk patients"}]},"trialDetails":[{"nctId":"NCT03029169","phase":"PHASE4","title":"Propafenone Versus Amiodarone in Septic Shock","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2017-10-23","conditions":"Supraventricular Arrhythmia, Septic Shock","enrollment":210},{"nctId":"NCT00920244","phase":"","title":"In-hospital Cardiac Arrest - Dynamics and State Transitions","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2009-08","conditions":"Heart Arrest, Death, Sudden, Cardiac","enrollment":285},{"nctId":"NCT00420953","phase":"PHASE1","title":"Relative Bioavailability of PM101 IV and Cordarone IV","status":"COMPLETED","sponsor":"Prism Pharmaceuticals","startDate":"2006-12-18","conditions":"Healthy","enrollment":""},{"nctId":"NCT02307591","phase":"PHASE2, PHASE3","title":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","sponsor":"Emergency NGO Onlus","startDate":"2014-12","conditions":"Ebola Virus Disease","enrollment":""},{"nctId":"NCT00121524","phase":"PHASE2","title":"Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome","status":"COMPLETED","sponsor":"Petter Andreas Steen","startDate":"2003-01","conditions":"Cardiac Arrest","enrollment":904}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DEATH"},{"count":2,"reaction":"HYPOTENSION"},{"count":2,"reaction":"REACTION TO EXCIPIENT"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antiarrhythmic therapy"],"phase":"marketed","status":"active","brandName":"Amiodarone i.v.","genericName":"Amiodarone i.v.","companyName":"Charles University, Czech Republic","companyId":"charles-university-czech-republic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amiodarone is a Class III antiarrhythmic that blocks potassium channels to prolong the action potential and refractory period, with additional effects on sodium, calcium, and beta-adrenergic channels. Used for Atrial fibrillation (acute conversion and maintenance of sinus rhythm), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}